Menu
Search
|

Menu

Close
X

Syneos Health Inc SYNH.OQ (NASDAQ Stock Exchange Global Select Market)

54.85 USD
+0.11 (+0.20%)
As of 3:59 PM EST
chart
Previous Close 54.74
Open 54.60
Volume 158,086
3m Avg Volume 220,843
Today’s High 55.00
Today’s Low 54.54
52 Week High 55.00
52 Week Low 31.10
Shares Outstanding (mil) 103.23
Market Capitalization (mil) 5,650.59
Forward P/E 98.50
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.85 Mean rating from 13 analysts

KEY STATS

Revenue (mm, USD)
FY18
3,245
FY17
2,672
FY16
1,611
EPS (USD)
FY18
-0.206
FY17
-0.491
FY16
2.028
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
98.50
36.06
Price to Sales (TTM)
vs sector
1.31
10.03
Price to Book (MRQ)
vs sector
1.99
4.62
Price to Cash Flow (TTM)
vs sector
16.38
26.63
Total Debt to Equity (MRQ)
vs sector
101.51
16.99
LT Debt to Equity (MRQ)
vs sector
98.74
13.50
Return on Investment (TTM)
vs sector
0.96
12.72
Return on Equity (TTM)
vs sector
1.98
13.74

EXECUTIVE LEADERSHIP

John Dineen
Chairman of the Board, Since 2018
Salary: --
Bonus: --
Paul Colvin
President - Clinical Solutions, Since 2019
Salary: --
Bonus: --
Alistair Macdonald
Chief Executive Officer, Director, Since 2016
Salary: $852,703.00
Bonus: --
Jason Meggs
Principal Financial Officer, Since 2019
Salary: --
Bonus: --
Lisa van Capelle
Chief Human Resource Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1030 Sync Street
MORRISVILLE   NC   27560

Phone: +1919.8769300

Syneos Health, Inc., formerly INC Research Holdings, Inc., is a global contract research organization (CRO). The Company focuses on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company's Clinical Development Services segment offers a range of clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.

SPONSORED STORIES